7 completed. 7 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Completed 7 |
Follow Polypoidal Choroidal Vasculopathy: new trials by email Literature Review of Polypoidal Choroidal Vasculopathy trials Research Report on Polypoidal Choroidal Vasculopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy Treat and Extend with Aflibercept 2mg, Fixed Dosing with Aflibercept 2mg - Age Related Macular Degeneration, Polypoidal Choroidal Vasculopathy | Phase 4 | Completed | Singapore National Eye Centre | 54 | 2017-12-01 | 2021-08-18 |
| Initial Versus Delayed PDT Combination With Conbercept in PCV conbercept, Initial PDT, Delayed PDT - Polypoidal Choroidal Vasculopathy | Phase 4 | Completed | The Eye Hospital of Wenzhou Medical University | 80 | 2017-01-01 | 2019-07-19 |
| Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy Intravitreal Aflibercept - Polypoidal Choroidal Vasculopathy | Phase 4 | Completed | Association for Innovation and Biomedical Research on Light and Image | 50 | 2015-11-23 | 2020-01-10 |
| Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy aflibercept - Exudative Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy | Phase 4 | Completed | Pusan National University Hospital | 48 | 2013-09-01 | 2016-04-29 |
| Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT) Ranibizumab, Verteporfin PDT, Sham PDT - Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy | Phase 4 | Completed | Novartis Pharmaceuticals | 321 | 2013-08-07 | 2019-06-07 |
| Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation Intravitreal aflibercept injection 2.0mg - Polypoidal Choroidal Vasculopathy | Phase 4 | Completed | Gregg T. Kokame, MD | 25 | 2013-05-01 | 2016-11-23 |
| Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy Verteporfin Photodynamic Therapy, Ranibizumab - Polypoidal Choroidal Vasculopathy | Phase 4 | Completed | Novartis | 61 | 2008-04-01 | 2011-04-19 |
Macular Degeneration (3) · Polyps (1)
Choroid Diseases (7) · Choroidal Neovascularization (7) · Eye Diseases (7) · Metaplasia (7) · Neovascularization, Pathologic (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Uveal Diseases (7) · Retinal Degeneration (3) · Retinal Diseases (3) · Pathological Conditions, Anatomical (1)
aflibercept (3) · Ranibizumab (2) · Verteporfin (2) · Coal Tar (1) · KH902 fusion protein (1)
Association for Innovation and Biomedical Research on Light and Image (1) · Gregg T. Kokame, MD (1) · Novartis (1) · Novartis Pharmaceuticals (1) · Pusan National University Hospital (1) · Singapore National Eye Centre (1) · The Eye Hospital of Wenzhou Medical University (1)
Singapore (3) · South Korea (3) · Hong Kong (2) · Taiwan (2) · Thailand (2) · China (1) · Japan (1) · Malaysia (1) · Portugal (1) · Spain (1) · United States (1)
Gemmy Cheung (1) · Gregg T. Kokame, MD, MMS (1) · Jae Pil Shin, MD, PhD (1) · Rufino Silva, PhD (1) · Xiaoling Liu, Professor (1)
PMID 22426346, PMID 25758601, PMID 27465105, PMID 28851779, PMID 28983556, PMID 32672800, PMID 33574033, PMID 34348351, PMID 35223882, PMID 38308746, PMID 40504425